An integrative review comparing recommendations from 9 international clinical guidelines on prenatal screening and diagnostic testing for fetal genetic abnormalities, covering NIPT, invasive procedures (amniocentesis, CVS), chromosomal microarray, and exome sequencing, based on guidelines published up to December 2025.
All 9 guidelines agreed on offering aneuploidy screening to all pregnant women and recognized NIPT as the most sensitive screening tool for common aneuploidies — but not a diagnostic replacement. Invasive testing (amniocentesis/CVS) remains the gold standard for confirmation. Chromosomal microarray is broadly recommended for fetal structural anomalies; routine prenatal exome sequencing is limited to selected cases. Key differences persist in screening implementation and uptake of emerging genomic technologies.
- Integrative (not systematic meta-analytic) review; qualitative synthesis only, no quantitative pooling. - Limited to guidelines published up to December 2025; very recently issued guidance may be missing. - Comparison across guidelines from different health systems may not reflect local resource or access constraints.
Offer NIPT to all pregnant patients as the most sensitive aneuploidy screen, but confirm positive results with amniocentesis or CVS before clinical action. Reserve chromosomal microarray for structural fetal anomalies, and consider exome sequencing only in selected high-complexity cases.
Explore related topics
